MNOV Share Price

Open 5.45 Change Price %
High 5.46 1 Day -0.20 -3.66
Low 5.24 1 Week -0.21 -3.84
Close 5.26 1 Month -0.69 -11.60
Volume 27381 1 Year -2.03 -27.85
52 Week High 8.00
52 Week Low 4.85
MNOV Important Levels
Resistance 2 5.46
Resistance 1 5.38
Pivot 5.32
Support 1 5.14
Support 2 5.06
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
DCTH 0.22 0.00%
FNFG 10.18 -0.20%
ASTI 0.00 0.00%
DELL 13.86 0.22%
QQQ 138.03 -1.81%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
More..
NASDAQ USA Top Gainers Stocks
LOCM 0.09 50.00%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
SMSI 1.62 24.62%
CGEI 0.22 22.22%
THTI 0.20 17.65%
MYRX 0.07 16.67%
BDMS 13.50 16.38%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
SPIR 0.01 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

MediciNova, Inc. (NASDAQ: MNOV)

MNOV Technical Analysis 4
As on 27th Jun 2017 MNOV Share Price closed @ 5.26 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 6.32 & Sell for SHORT-TERM with Stoploss of 5.61 we also expect STOCK to react on Following IMPORTANT LEVELS.
MNOV Target for June
1st Target up-side 6.26
2nd Target up-side 6.57
3rd Target up-side 6.88
1st Target down-side 5.38
2nd Target down-side 5.07
3rd Target down-side 4.76
MNOV Other Details
Segment EQ
Market Capital 35637184.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.medicinova.com
MNOV Address
MNOV
4275 Executive Square
Suite 650
San Diego, CA 92037
United States
Phone: 858-373-1500
MNOV Latest News
Interactive Technical Analysis Chart MediciNova, Inc. ( MNOV NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on MediciNova, Inc.
MNOV Business Profile
MediciNova, Inc. is a development-stage biopharmaceutical company focused on acquiring and developing small molecule therapeutics for the treatment of serious diseases with unmet medical needs with a focus on the United States market. Through strategic alliances, primarily with Japanese pharmaceutical companies, it holds rights to a diversified portfolio of clinical and preclinical product candidates. The Company has relationships with a number of pharmaceutical companies, including Kissei Pharmaceutical Co., Ltd. (Kissei Pharmaceutical), Kyorin Pharmaceutical Co., Ltd. (Kyorin Pharmaceutical), Mitsubishi Tanabe Pharma Corporation and Meiji Seika Kaisha, Ltd. (Meiji Seika Kaisha) in Japan and Angiogene Pharmaceuticals, Ltd. (Angiogene Pharmaceuticals) in the United Kingdom, pursuant to which the Company has obtained rights to develop and commercializes its product candidates.